Drug Trial Radar · NCT07544628
A Phase 1 Study of Navlimetostat Tablet Formulations
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Nov 2, 2026
Study completion Nov 2, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
Conditions
- Healthy Participants
Interventions
NavlimetostatDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax)Time frame: Up to Day 17
- Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]Time frame: Up to Day 17
- Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: Up to Day 17
- Number of participants with Adverse Events (AE)Time frame: Up to approximately day 37
- Number of participants with Serious Adverse Events (AE)Time frame: Up to approximately day 37
- Number of participants with clinically significant changes in Physical Examinations (PE)Time frame: Up to Day 17
- Number of participants with clinically significant changes in vital signs (VS)Time frame: Up to Day 17
- Number of participants with clinically significant changes in 12-lead ECGsTime frame: Up to Day 17
- Number of participants with clinically significant changes in laboratory tests resultsTime frame: Up to Day 17
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
CenExel iResearch - Decatur
Decatur, Georgia · Recruiting
Local Institution - 0003
Decatur, Georgia · Withdrawn
Local Institution - 0001
Austin, Texas · Withdrawn
Local Institution - 0004
Austin, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.